Complimentary access to the JTO and a 25% discount on the publication fees for the newest open-access IASLC journal, JTO CRR. Both JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology.
JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. With an Impact Factor of 15.609, JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology. It emphasizes a multidisciplinary approach and includes original research, reviews and opinion pieces. JTO CRR, IASLC’s open access companion title, publishes a range of manuscripts from subset analyses of published trials to high-quality case reports. JTO CRR is indexed in PubMed Central.
JTO by the Numbers
Recent journal articles
Effects of Ethnicity on Outcomes of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Treated with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKI) and Surgical Resection
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With Non-Small Cell Lung Cancer
Clinical Characteristics and Outcomes in Advanced KRAS-mutated NSCLC: a multi-center collaboration in Asia (ATORG-005)
Life-Threatening Myositis in a Patient with EGFR-mutated NSCLC on Osimertinib: case report
EGFR-mutated lung adenocarcinoma successfully treated with osimertinib after spontaneous transformation into small cell lung cancer and adenocarcinoma with neuroendocrine differentiation: case report
Lung Cancer Screening Considerations During Respiratory Infection Outbreaks, Epidemics or Pandemics: An IASLC Early Detection and Screening Committee Report
Pitfalls in cancer evaluation in case of chronic superior vena cava obstruction: vertebral enhancement and hot quadrate sign in the liver.
Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients with Lung Adenocarcinoma after Complete Resection: Results From the ICAN Study
Discover the JTO
More than 80 international experts compose the JTO Editorial Board, allowing for a quick turn-around time of 5.4 days to initial decision, and an average of 7 days for revisions, a fast track category, publish on acceptance (within 5 days), and promotion of select articles via social media and press releases.
JTO emphasizes a multidisciplinary approach and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. Authors can take advantage of Elsevier's Researcher Academy, Navigate your research journey with Researcher Academy—free e-learning modules on navigating your career developed by global experts.